PMID-19386527 – CJC-1295 GH-IGF-1 Axis Serum Protein Changes
Sackmann-Sala L, Ding J, Frohman LA, Bhatt DK. Proteomic analysis of serum proteins from growth hormone-releasing hormone analog (CJC-1295)-treated adult men. Growth Horm IGF Res. 2009;19(5):424-428.
Quick Reference
| Property | Value |
|---|---|
| PMID | 19386527 |
| DOI | 10.1016/j.ghir.2009.03.001 |
| Year | 2009 |
| Journal | Growth Hormone & IGF Research |
| Study Type | Human clinical (proteomic analysis) |
| Evidence Level | III |
| Sample | 11 healthy adult men |
| Peptide(s) Studied | CJC-1295 NO DAC |
Key Findings
- Proteomic analysis of serum from 11 healthy men treated with CJC-1295 identified 5 proteins with significant intensity changes
- Provided molecular-level evidence of GH/IGF-1 axis activation beyond simple hormone level measurements
- Changes in serum protein expression patterns confirmed systemic biological response to CJC-1295
- The proteomic approach offers a richer picture of CJC-1295's physiological effects than hormone-level monitoring alone
- Identified potential biomarkers for monitoring GH secretagogue therapy response
- Results were consistent with known GH/IGF-1 downstream signaling effects
Study Design
Serum samples from 11 healthy adult men who received CJC-1295 were analyzed using 2D gel electrophoresis and mass spectrometry-based proteomics. Pre-treatment and post-treatment serum samples were compared. Differentially expressed proteins were identified by peptide mass fingerprinting. Statistical analysis identified proteins with significant changes in expression intensity.
Limitations
- Very small sample size (n=11) limits statistical power and generalizability
- No placebo control group for the proteomic analysis
- 2D gel electrophoresis has limited dynamic range and may miss low-abundance proteins
- Functional significance of the identified protein changes was not fully explored
- No validation by orthogonal methods (Western blot, ELISA) reported
- Study does not distinguish direct CJC-1295 effects from secondary effects of GH/IGF-1 elevation
Clinical Relevance
This study advances the understanding of CJC-1295's systemic effects beyond GH and IGF-1 levels alone. For practitioners, it provides evidence that CJC-1295 produces measurable, multi-system biological effects consistent with physiological GH axis activation. The identification of serum protein biomarkers could eventually enable more nuanced monitoring of patients on GH secretagogue therapy, moving beyond simple IGF-1 measurements to a broader assessment of treatment response.
Related
#research #observational #CJC-1295 #evidence-level-III